More about Coris Bioconcept's Ag Respi Strip
Coris BioConcept - in close collaboration with;
The University Hospital Laboratory of Brussels, the Karolinska Institute in Stockholm, the University of Milan and the Institute of Virology in Leipzig and the support of the National Reference Centre for Respiratory Pathogens as well as the laboratory of the University Hospital of Liège
- developed a rapid diagnostic test making it possible to detect the SARS-COV-2 virus in patients with severe infection.
The product gives results in 30 minutes
- Sensitivity – Specificity:
The kit was evaluated in GP clinic settings (USA) with a panel of 189 nasopharyngeal
swabs using the dry swab procedure. Samples status was confirmed using RT-PCR
(Ct range of positive samples: 14.9 - 34).
- Sensitivity 91.2%
- Specificity 99.4%
- Positive Predictive Value 96.9%
- Negative Predictive Value 98.1%
- Agreement 97.9%
We recommend you read our page on 3 important aspects of CoVID-19 infections pertaining to diagnostic tests and their performance parameters Click HERE
Hospital ICU Algorithm CLSI Article
An algorithm is proposed whereby patients are screened with Ag Respi-Strip. Decisions concerning isolation and cohorting can be made on positive results, negative results are submitted for qPCR.
This test is CE marked and will be an excellent complement to the molecular biology screening methods currently used in hospitals. A paper covering the development and clinical performance of the Ag Respi-Strip assay has been submitted for publication.
Ag-Respi Strip is CE marked.